Literature DB >> 27122956

Regorafenib-Related Myocardial Injury during Atrial Fibrillation.

Fu-Chih Hsiao1, Chun-Nan Yeh2, Pao-Hsien Chu1.   

Abstract

UNLABELLED: Multikinase inhibitors with an anti-vascular endothelial growth factor effect have been reported to increase the risk of myocardial infarction or ischemia. We have presented the case of a 72-year-old male who had a metastatic gastrointestinal stromal tumor for which he received targeted therapy and who was admitted to our hospital for recurrent episodes of myocardial injury during atrial fibrillation. Coronary angiography showed insignificant coronary artery stenosis. We also reviewed the incidence of cardiovascular events in patients receiving regorafenib, and the current understanding of the mechanism of targeted therapy-induced myocardial ischemia/infarction. KEY WORDS: Multikinase inhibitor • Myocardial infarction • Myocardial ischemia • Vascular endothelial growth factor.

Entities:  

Year:  2016        PMID： 27122956      PMCID： PMC4816924          DOI： 10.6515/acs20150629b

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN： 1011-6842            Impact factor:   2.672


  10 in total

Review 1.  Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.

Authors:  Omar Abdel-Rahman; Mona Fouad
Journal:  Crit Rev Oncol Hematol       Date:  2014-07-01       Impact factor: 6.312

2.  Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.

Authors:  Scott M Wilhelm; Jacques Dumas; Lila Adnane; Mark Lynch; Christopher A Carter; Gunnar Schütz; Karl-Heinz Thierauch; Dieter Zopf
Journal:  Int J Cancer       Date:  2011-04-22       Impact factor: 7.396

Review 3.  Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis.

Authors:  Zexing Wang; Jing Xu; Weiwei Nie; Guichun Huang; Jinhai Tang; Xiaoxiang Guan
Journal:  Eur J Clin Pharmacol       Date:  2013-10-23       Impact factor: 2.953

Review 4.  Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.

Authors:  Thomas Force; Daniela S Krause; Richard A Van Etten
Journal:  Nat Rev Cancer       Date:  2007-05       Impact factor: 60.716

Review 5.  Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics.

Authors:  Ming Hui Chen; Risto Kerkelä; Thomas Force
Journal:  Circulation       Date:  2008-07-01       Impact factor: 29.690

Review 6.  Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis.

Authors:  Wei-Xiang Qi; Zan Shen; Li-Na Tang; Yang Yao
Journal:  Crit Rev Oncol Hematol       Date:  2014-05-02       Impact factor: 6.312

Review 7.  Cardiotoxicity induced by tyrosine kinase inhibitors.

Authors:  George S Orphanos; George N Ioannidis; Alexandros G Ardavanis
Journal:  Acta Oncol       Date:  2009       Impact factor: 4.089

8.  Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  George D Demetri; Peter Reichardt; Yoon-Koo Kang; Jean-Yves Blay; Piotr Rutkowski; Hans Gelderblom; Peter Hohenberger; Michael Leahy; Margaret von Mehren; Heikki Joensuu; Giuseppe Badalamenti; Martin Blackstein; Axel Le Cesne; Patrick Schöffski; Robert G Maki; Sebastian Bauer; Binh Bui Nguyen; Jianming Xu; Toshirou Nishida; John Chung; Christian Kappeler; Iris Kuss; Dirk Laurent; Paolo G Casali
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

9.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

10.  Clinical cardiac safety profile of nilotinib.

Authors:  Theo D Kim; Philipp le Coutre; Michaela Schwarz; Peggy Grille; Michal Levitin; Suzanne Fateh-Moghadam; Francis J Giles; Bernd Dörken; Wilhelm Haverkamp; Clemens Köhncke
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941
  10 in total
  2 in total

Review 1.  A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors.

Authors:  Ying Jin; Zhifei Xu; Hao Yan; Qiaojun He; Xiaochun Yang; Peihua Luo
Journal:  Front Pharmacol       Date:  2020-06-12       Impact factor: 5.810

2.  Therapeutic Potential of Regorafenib-A Multikinase Inhibitor in Pulmonary Hypertension.

Authors:  Swathi Veeroju; Baktybek Kojonazarov; Astrid Weiss; Hossein Ardeschir Ghofrani; Norbert Weissmann; Friedrich Grimminger; Werner Seeger; Tatyana Novoyatleva; Ralph T Schermuly
Journal:  Int J Mol Sci       Date:  2021-02-02       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.